Welcome to the e-CCO Library!

P502: Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implications
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

x. Cortés*1, J. R. MOLÉS2, S. Fernández3, J. Clofent3, M. Moreno4, J. Rodriguez3, J. Primo3

Created: Friday, 22 February 2019, 9:49 AM
P502: Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zezos P.*1, Kabakchiev B.2, Weizman A.V.1, Nguyen G.C.1, Narula N.1, Croitoru K.1, Steinhart A.H.1, Silverberg M.S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Gonzalez Lama, M. Calvo, V. Matallana, I. Gonzalez-Partida, I. Omella, M.I. Vera

Created: Thursday, 30 January 2020, 10:12 AM
P503: Can daily SCCAI measurements over a 6-month period better phenotype the pattern of disease in ulcerative colitis?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1*, A. Kormilitzin2, C. Hinds3, V. Sexton4, J. Wilson1, M. Peters5, O. Brain1, S. Keshav1, H. Uhlig1, J. Geddes4, G. Goodwin4, G. Collins6, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P503: Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort study
Year: 2022
Source: ECCO'22
Authors: Schneider, R.(1,2);Jacobson, K.(3);Huynh, H.(4);Mack, D.(5);Deslandres, C.(6);deBruyn, J.(7);El-Matary, W.(8);Otley, A.(9);Lawrence, S.(3);Wine, E.(4);Sherlock, M.(10);Critch, J.(11);Jantchou, P.(6);Rashid, M.(9);Carroll, M.(4);Bax, K.(12);Seidman, E.(13);Benchimol, E.(1,2);Ricciuto, A.(1,2);Wu, A.(1);Pullenayegum, E.(2);Walters, T.(1);Nguyen, G.(2);Griffiths, A.(1,2);Church, P.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P503: Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics
Year: 2021
Source: ECCO'21 Virtual
Authors: Todeschini, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P503: Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ametzazurra A.1, Rivera N.2, Hernández A.M.1, Arreba M.P.3, Ruiz E.4, Ortíz J.3, Muñoz M.d.C.3, Torres N.1, Pascual J.1, Martínez A.1, Allande M.J.2, Nagore D.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P503: Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae, K. Matsumoto

Created: Friday, 22 February 2019, 9:49 AM
P503: The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQ
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rezazadeh Ardabili, A.(1,2)*;van Esser, D.(1);Wintjens, D.(1);Cilissen, M.(1);Deben, D.(3);Mujagic, Z.(1,2);Russ, F.(4);Stassen, L.(2,5);van Bodegraven, A.(4);Wong, D.(3);Winkens, B.(6);Jonkers, D.(1,2);Romberg-Camps, M.(4);Pierik, M.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P503: Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Biemans*1, J. van der Woude2, G. Dijkstra3, A. van der Meulen-de Jong4, B. Oldenburg5, N. de Boer6, M. Löwenberg7, N. Srivastava8, J. Jansen9, R. West10, A. de Vries2, J. Haans11, M. Pierik11, F. Hoentjen12

Created: Friday, 22 February 2019, 9:41 AM
P504 Remote cannabis-therapy management platform for IBD patients: performance assessment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Sweed1, C. Shapira2, T. Naftali3

Created: Thursday, 30 January 2020, 10:12 AM
P504: Differences between paediatric and adult inflammatory bowel disease presentation – analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy – Satimos study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sieczkowska-Golub J.*1, Jarzebicka D.1, Borys-Iwanicka A.2, Korlatowicz-Bilar A.3, Szaflarska-Popławska A.4, Grzybowska-Chlebowczyk U.5, Łazowska-Przeorek I.6, Daniluk U.7, Korczowski B.8, Sordyl B.9, Szczepanik M.10, Landowski P.11, Plocek A.12, Bąk-Drabik K.13, Zagorowicz E.14, Kierkus J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P504: Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Fumery, M.(1);Filippi, J.(2);Abitbol, V.(3);Biron, A.(4);Laharie, D.(5);Serrero, M.(6);Altwegg, R.(7);Bouhnik, Y.(8);Peyrinbiroulet, L.(9);Gilletta, C.(10);Roblin, X.(11);Pineton de Chambrun, G.(12);Vuitton, L.(13);Bourrier, A.(14);Nancey, S.(15);Gornet, J.M.(16);Nahon, S.(17);Bouguen, G.(18);Viennot, S.(19);Pariente, B.(20);Amiot, A.(21);
Created: Wednesday, 2 June 2021, 4:12 PM
P504: Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Atreya, R.(1)*;Abreu, M.T.(2);Krueger, J.G.(3);Eyerich, K.(4,5);Sachen, K.(6);Greving, C.(6);Hammaker, D.(6);Bao, P.(6);Lacy, E.(7);Sarabia, I.(6);Deming, J.(6);Elloso, M.M.(8);Ritchlin, C.(9);McInnes, I.B.(10);Allez, M.(11);Fourie, A.(6);
Created: Friday, 14 July 2023, 11:05 AM
P504: How acceptable is a ‘treat to target’ (T2T) approach to IBD patients in clinical remission?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Carbonell1, J. Kane1, M. Omer1, A. Odouri Ochieng1, M. Pinder1, R. McKay1, J. Hamlin1, C. Selinger*1

Created: Friday, 22 February 2019, 9:41 AM
P504: Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Brownson, E.(1);Saunders, J.(1);Gerasimidis, K.(2);Karafoulidou, Z.(2);Seenan, J.P.(1);Macdonald, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P504: Stability observations in tacrolimus suppositories
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Lie*1, E. Jansen2, P. Hoeben2, R. Zaal3, D. Hodes2, M. Rosman2, W. Loos2, J. van der Woude1

Created: Friday, 22 February 2019, 9:49 AM
P504: The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Sollelis1,2*, R. Minet Quinard3, G. Bouguen4, M. Goutte1,2, F. Goutorbe1,5, D. Bouvier3, B. Pereira6, G. Bommelaer1,2, A. Buisson1,2

Created: Thursday, 21 February 2019, 9:14 AM
P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Rosembert1, A. Malaviya2, J. How2, J. Tomlison3, F. Toh3, M. Roe1, A. Nightingale4, C. Garcia-Sueiro4, P. Herbert4, D. Jadon2, P. Norris3, J. Thomas3, J. Magsino4, A. Negoescu2, T. Raine4

Created: Thursday, 30 January 2020, 10:12 AM
P505: Early therapeutic drug monitoring after induction therapy with infliximab: correlation with intestinal ultrasound
Year: 2021
Source: ECCO'21 Virtual
Authors: Nascimento, C.(1);Morão, B.(1);Frias Gomes, C.(1);Cúrdia Gonçalves, T.(2);Castro, F.(2);Moreira, M.(2);Cotter, J.(2);Pereira, F.(3);Caldeira, A.(3);Sousa, R.(3);Coelho, R.(4);Macedo, G.(4);Macedo, C.(5);Ferreira, M.(5);Cravo, M.(1);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM